132 related articles for article (PubMed ID: 36858142)
1. Novel Symptom Subgroups in Individuals With Irritable Bowel Syndrome Predict Disease Impact and Burden.
Black CJ; Ng CE; Goodoory VC; Ford AC
Clin Gastroenterol Hepatol; 2024 Feb; 22(2):386-396.e10. PubMed ID: 36858142
[TBL] [Abstract][Full Text] [Related]
2. A Novel Method to Classify and Subgroup Patients With IBS Based on Gastrointestinal Symptoms and Psychological Profiles.
Black CJ; Yiannakou Y; Guthrie EA; West R; Houghton LA; Ford AC
Am J Gastroenterol; 2021 Feb; 116(2):372-381. PubMed ID: 33110014
[TBL] [Abstract][Full Text] [Related]
3. Latent class analysis does not support the existence of Rome IV functional bowel disorders as discrete entities.
Black CJ; Houghton LA; Ford AC
Neurogastroenterol Motil; 2022 Nov; 34(11):e14391. PubMed ID: 35531932
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome.
Goodoory VC; Guthrie EA; Ng CE; Black CJ; Ford AC
Aliment Pharmacol Ther; 2023 Feb; 57(3):323-334. PubMed ID: 36544055
[TBL] [Abstract][Full Text] [Related]
5. Novel Irritable Bowel Syndrome Subgroups are Reproducible in the Global Adult Population.
Black CJ; Houghton LA; West RM; Bangdiwala SI; Palsson OS; Sperber AD; Ford AC
Clin Gastroenterol Hepatol; 2024 Jun; ():. PubMed ID: 38876193
[TBL] [Abstract][Full Text] [Related]
6. Impact of Rome IV irritable bowel syndrome on work and activities of daily living.
Goodoory VC; Ng CE; Black CJ; Ford AC
Aliment Pharmacol Ther; 2022 Sep; 56(5):844-856. PubMed ID: 35794733
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome.
Goodoory VC; Ng CE; Black CJ; Ford AC
Aliment Pharmacol Ther; 2023 May; 57(10):1083-1092. PubMed ID: 36914979
[TBL] [Abstract][Full Text] [Related]
8. Utility of irritable bowel syndrome subtypes and most troublesome symptom in predicting disease impact and burden.
Khasawneh M; Shaikh FA; Ng CE; Black CJ; Goodoory VC; Ford AC
Neurogastroenterol Motil; 2024 Apr; 36(4):e14756. PubMed ID: 38321517
[TBL] [Abstract][Full Text] [Related]
9. Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom.
Goodoory VC; Ng CE; Black CJ; Ford AC
Aliment Pharmacol Ther; 2022 Jul; 56(1):110-120. PubMed ID: 35491477
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value.
Black CJ; Yiannakou Y; Guthrie E; West R; Houghton LA; Ford AC
Aliment Pharmacol Ther; 2021 May; 53(10):1126-1137. PubMed ID: 33705578
[TBL] [Abstract][Full Text] [Related]
11. Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT.
Everitt H; Landau S; Little P; Bishop FL; O'Reilly G; Sibelli A; Holland R; Hughes S; Windgassen S; McCrone P; Goldsmith K; Coleman N; Logan R; Chalder T; Moss-Morris R
Health Technol Assess; 2019 Apr; 23(17):1-154. PubMed ID: 31042143
[TBL] [Abstract][Full Text] [Related]
12. Patients suspected of irritable bowel syndrome--cross-sectional study exploring the sensitivity of Rome III criteria in primary care.
Engsbro AL; Begtrup LM; Kjeldsen J; Larsen PV; de Muckadell OS; Jarbøl DE; Bytzer P
Am J Gastroenterol; 2013 Jun; 108(6):972-80. PubMed ID: 23419383
[TBL] [Abstract][Full Text] [Related]
13. Cumulative Effect of Psychological Alterations on Gastrointestinal Symptom Severity in Irritable Bowel Syndrome.
Midenfjord I; Borg A; Törnblom H; Simrén M
Am J Gastroenterol; 2021 Apr; 116(4):769-779. PubMed ID: 33982947
[TBL] [Abstract][Full Text] [Related]
14. Mixture model analysis identifies irritable bowel syndrome subgroups characterised by specific profiles of gastrointestinal, extraintestinal somatic and psychological symptoms.
Polster A; Van Oudenhove L; Jones M; Öhman L; Törnblom H; Simrén M
Aliment Pharmacol Ther; 2017 Sep; 46(5):529-539. PubMed ID: 28671338
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea.
Buono JL; Carson RT; Flores NM
Health Qual Life Outcomes; 2017 Feb; 15(1):35. PubMed ID: 28196491
[TBL] [Abstract][Full Text] [Related]
16. Natural History and Disease Impact of Rome IV Vs Rome III Irritable Bowel Syndrome: A Longitudinal Follow-Up Study.
Goodoory VC; Houghton LA; Yiannakou Y; Black CJ; Ford AC
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):569-577.e3. PubMed ID: 33957271
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III Criteria.
Black CJ; Yiannakou Y; Houghton LA; Ford AC
Clin Gastroenterol Hepatol; 2020 Feb; 18(2):392-398.e2. PubMed ID: 31154027
[TBL] [Abstract][Full Text] [Related]
18. Anxiety-related factors associated with symptom severity in irritable bowel syndrome.
Black CJ; Yiannakou Y; Houghton LA; Shuweihdi F; West R; Guthrie E; Ford AC
Neurogastroenterol Motil; 2020 Aug; 32(8):e13872. PubMed ID: 32396247
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and impact of self-reported irritable bowel symptoms in the general population.
Van den Houte K; Carbone F; Pannemans J; Corsetti M; Fischler B; Piessevaux H; Tack J
United European Gastroenterol J; 2019 Mar; 7(2):307-315. PubMed ID: 31080615
[TBL] [Abstract][Full Text] [Related]
20. Reduction in IBS symptom severity is not paralleled by improvement in quality of life in patients with irritable bowel syndrome.
Weerts ZZRM; Vork L; Mujagic Z; Keszthelyi D; Hesselink MAM; Kruimel J; Leue C; Muris JWM; Jonkers DMAE; Masclee AAM
Neurogastroenterol Motil; 2019 Aug; 31(8):e13629. PubMed ID: 31119844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
